<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334930</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2013/34</org_study_id>
    <nct_id>NCT02334930</nct_id>
  </id_info>
  <brief_title>Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors</brief_title>
  <acronym>PEC-Hem</acronym>
  <official_title>Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PEComa is rare tumor affecting particularly patients with Tuberous Sclerosis. Biological
      similarities were seen between PEComa and infantile hemangioma. Propranolol is highly
      efficient to treat infantile hemangioma and we believe that this drug can also be useful for
      the treatment of PEComa.

      Purpose : to understand the mechanism of action of propranolol in PEComas and related
      pediatric vascular lesions and to select possible novel targets of betablockers in vascular
      tumors related to PEComas by using YAP oncogene activation as a molecular marker
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>YAP cellular expression by immunohistochemistry study on collected tissues</measure>
    <time_frame>At inclusion (day 0)]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta adrenergic receptors expression by immunohistochemistry study on collected tissues</measure>
    <time_frame>At inclusion (day 0)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of Hippo/YAP pathway expression by western-blot, and correlation with propranolol efficacy</measure>
    <time_frame>At inclusion (day 0)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of MAP/kinases pathway expression by western-blot, and correlation with propranolol efficacy</measure>
    <time_frame>At inclusion (day 0)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of PKA/AMPc pathway expression by western-blot, and correlation with propranolol efficacy</measure>
    <time_frame>At inclusion (day 0)]</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">13</enrollment>
  <condition>PEComa</condition>
  <condition>Hemangioma</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients who will have biopsy or surgery for Perivascular epithelioid cell tumor (PEComa) or vascular pediatric tumor (Rapidly Involuting Congenital Hemangioma (RICH), Non Involuting Congenital Hemangioma (NICH), hemangioma or pyogenic granuloma)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who will have biopsy or surgery for PEComa or vascular pediatric tumor (RICH,
        NICH, hemangioma or pyogenic granuloma)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who will have biopsy or surgery for PEComa or vascular pediatric tumor (RICH,
             NICH, hemangioma or pyogenic granuloma)

          -  A free, informed and written consent will be established

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2015</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>propranolol</keyword>
  <keyword>betablocker</keyword>
  <keyword>angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Perivascular Epithelioid Cell Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

